Journal
CANCER LETTERS
Volume 278, Issue 1, Pages 82-87Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.12.034
Keywords
Synergy; 5-aza-2'-deoxycytidine; Paclitaxel; Prostate carcinoma
Categories
Funding
- Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry
Ask authors/readers for more resources
To determine the synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel (M) against prostate carcinoma (PC) cells by isobolographic analysis. We demonstrated that DAC could significantly increase the susceptibility of PC cells to M, and confirmed the synergy of DAC and PTX DAC enhanced the PTX induced up-regulation of caspase activity and anti-proliferative effect, resulting in an increase of cells in subG1 and G2/M phases. In addition, the synergy was observed in both androgen-dependent and -independent PC cell lines. It suggested that combination chemotherapy with DAC and PTX might be a new strategy to improve the clinical response rate of PC. Crown Copyright (c) 2009 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available